Study to Evaluate the Feasibility of Twice Daily Use of Topical Azelaic Acid in Breast Cancer Patients Undergoing Radiation

Part of paid clinical trials in Richmond, Virginia.

Sponsor
Virginia Commonwealth University
Study ID
NCT06966388
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Azelaic Acid — DRUG
    A thin layer of Azelaic acid should be applied to the entire area of radiation treatment twice daily, each day of the week (including weekends) starting one week prior to the start of radiation, then during the entire course of radiation treatment (usually 3-5 weeks), and for 3 weeks following the completion of radiation treatment.

Study Details

This pilot study will evaluate the feasibility of at least twice daily use of azelaic acid in breast cancer patients undergoing radiation treatment.

Key Dates

Start date
Aug 13, 2025
Status verified
Jan 2026
Primary completion
Nov 30, 2026
Completion
Nov 30, 2026

Study Design

Enrollment
33 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: Topical Azelaic Acid
    Twice daily application of azelaic acid

Primary Outcome Measure

Determine the feasibility of twice daily use of topical azelaic acid in patients undergoing breast radiation therapy [ Time Frame: One week prior to radiation treatment, daily during radiation treatment up to 5 weeks, three weeks following radiation treatment ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Virginia Commonwealth UniversityRichmondVirginia23298
Massey CTO CPC Team
[email protected]
804-628-6430
Todd C. Adams, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Richmond, VA

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
Virginia Commonwealth University· Richmond, VA

Related Studies